<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744430</url>
  </required_header>
  <id_info>
    <org_study_id>H-38959</org_study_id>
    <nct_id>NCT02744430</nct_id>
  </id_info>
  <brief_title>Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain</brief_title>
  <official_title>A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be a prospective randomized double-blind placebo-controlled trial of&#xD;
      mirabegron for medical expulsive therapy (MET) in patients with a CT (Computed Tomography)&#xD;
      scan-proven ureteral stone between 4 to 10 mm undergoing expectant management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a prospective randomized double-blind placebo-controlled trial of&#xD;
      mirabegron for medical expulsive therapy (MET) in patients with a CT scan-proven ureteral&#xD;
      stone between 4 to 10 mm undergoing expectant management. Subjects will be distributed at a&#xD;
      1:1 ratio between the control and treatment groups. The treatment group will receive&#xD;
      mirabegron and the control groups will receive a placebo. Both groups will receive analgesics&#xD;
      and hydration will be recommended. All subjects will then be followed for 30 days to&#xD;
      determine the proportion of subjects with spontaneous passage. Patients will record narcotic&#xD;
      usage and pain scores during this time. If there is stone persistence in the ureter based on&#xD;
      imaging (CT scan of the abdomen and pelvis versus renal ultrasound plus KUB), then the&#xD;
      patient will undergo ureteroscopy with stent placement. In these patients, treatment will&#xD;
      continue while the stent is in place and patients will fill out a validated questionnaire&#xD;
      regarding stent pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2017</start_date>
  <completion_date type="Actual">October 31, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous stone passage using Fisher's exact test</measure>
    <time_frame>30 days</time_frame>
    <description>The primary analysis will compare the proportion of subjects with spontaneous stone passage within 30 days between study groups using Fisher's exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of pain levels between treatment groups using the Wong Baker FACES pain scale</measure>
    <time_frame>2 months</time_frame>
    <description>Pain measures between treatment groups will be measured daily for each patient by using the Wong Baker FACES pain scale. The Ureteric Stent Symptoms Questionnaire (USSQ) will be observed in patients who require surgical intervention, and will be observed during study visit 4. A general linear model will be used to compare USSQ (Ureteric Stent Symptoms Questionnaire) pain scores between the treated and placebo groups. The model will also be used to explore associations between pain scores and demographic or clinical characteristics adjusting for treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Ureteral Obstruction</condition>
  <condition>Flank Pain</condition>
  <arm_group>
    <arm_group_label>Arm 1 - Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirabegron 50 mg orally once every 24 hours starting immediately</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally once every 24 hours starting immediately</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <description>Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus &gt;5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.</description>
    <arm_group_label>Arm 1 - Active</arm_group_label>
    <other_name>Myrbetriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus &gt;5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.</description>
    <arm_group_label>Arm 2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Single unilateral ureteral calculus 4 to 10 mm visible on CT scan within the ureter&#xD;
&#xD;
          -  Serum creatinine within normal range&#xD;
&#xD;
          -  Ability to tolerate oral fluids and oral pain medication&#xD;
&#xD;
          -  Able to make informed medical decisions regarding consent&#xD;
&#xD;
          -  Willingness to follow-up in the Urology Clinic in approximately 30 day&#xD;
&#xD;
          -  Willing to undergo ureteroscopic extraction should the stone not pass in this time&#xD;
             period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Age less than 18&#xD;
&#xD;
          -  Multiple stones&#xD;
&#xD;
          -  Solitary kidney&#xD;
&#xD;
          -  Horseshoe kidney&#xD;
&#xD;
          -  On immunosuppressant therapy&#xD;
&#xD;
          -  On digoxin&#xD;
&#xD;
          -  Uncontrolled hypertension (Systolic blood pressure &gt; 170, diastolic blood pressure &gt;&#xD;
             110)&#xD;
&#xD;
          -  History of ureteral surgery or previous endoscopic procedure&#xD;
&#xD;
          -  Allergy to mirabegron&#xD;
&#xD;
          -  Current calcium antagonist or corticosteroid or tamsulosin usage&#xD;
&#xD;
          -  Patients already taking a beta-adrenergic agonist medication&#xD;
&#xD;
          -  Renal insufficiency [Glomerular Filtration Rate (GFR) less than 60]&#xD;
&#xD;
          -  Patients with Childs B and C liver failure&#xD;
&#xD;
          -  Signs of infection i. Temperature greater than 38 degrees Celsius ii. Urinalysis with&#xD;
             any of the following positive:&#xD;
&#xD;
               1. Positive nitrites&#xD;
&#xD;
               2. White blood cell count greater than 15/hpf (high powered field)&#xD;
&#xD;
               3. Positive urine culture [defined as a single isolated bacterial species population&#xD;
                  of greater than 100,000 Colony Forming Units (CFU)]&#xD;
&#xD;
          -  Patients with chronic pain already undergoing treatment with narcotic medications&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  No working phone number&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley A. Mayer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ben Taub General Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2016</study_first_posted>
  <last_update_submitted>January 31, 2020</last_update_submitted>
  <last_update_submitted_qc>January 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Wesley Adam Mayer</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Medical expulsive therapy</keyword>
  <keyword>ureteral stone</keyword>
  <keyword>stent pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
    <mesh_term>Ureteral Obstruction</mesh_term>
    <mesh_term>Flank Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be published in a aggregate format after completion of study.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>October 2, 2020</submitted>
    <returned>October 27, 2020</returned>
    <submitted>January 12, 2021</submitted>
    <returned>January 29, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

